×

Government Agencies FDA

  • Dr. Marty Makary of Johns Hopkins University Hospital

    The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.

  • A surgeon looks through the da Vinci surgical system's monitor.

    Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.

  • San Diego

    San Diego is at ease with sandy beaches, and biotechnology.

  • Johnson & Johnson Hits All-Time High

    Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.

  • Nutritional information is printed on the wrapper of a McDonald's Egg McMuffin in San Rafael, California

    Most big chain restaurants now put nutrition information on their menus. How accurate are these numbers? NBC News takes a closer look.

  • In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.

  • "It's going to look more like the rounding error in GDP," says one economist. "I think there is a lot more noise than light being shed on the sequester."

  • U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.

  • NPS Pharmaceuticals CEO on Gattex's FDA Approval

    NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.

  • NPS Pharmaceuticals CEO on Orphan Drugs

    NPS Pharmaceuticals president & CEO Dr. Francois Nader, discusses strategies his company uses to finding value for shareholders, and appealing to the FDA.

  • Options Action: Monster Beverage Comeback?

    One options trader is making a big bet on Monster Beverage amid the stock's decline, with CNBC contributor Mike Khouw of CRT Capital Group LLC.

  • Monster Beverage Unaware of Fatality Caused By Drinks

    Monster Beverage responds to the five deaths reported to the FDA citing the energy drink, reports CNBC's Eamon Javers.

  • F.D.A. Receives Death Reports Citing Popular Energy Drink

    Five people may have died in recent years after drinking Monster Energy, a popular energy drink that is high in caffeine, according to incident reports recently released by the Food and Drug Administration.

  • Monster Beverage Stock Sinks

    Monster Beverage is sinking after reports that 5 people may have died after drinking the popular Monster energy drink, with CNBC's Herb Greenberg. Bill Chapell, Suntrust Robinson Humphrey analyst, weighs in.

  • FDA Recieves Death Reports Citing Monster Energy Drink

    Monster Beverage is down about 9 percent today on reports that 5 people may have died after drinking the popular Monster energy drink, reports CNBC's Jackie DeAngelis.

  • An Iran Revolution Coming?

    Discussing whether an Iranian currency collapse could lead to a revolution, with Peter Brookes, former Deputy Assistant Secretary of Defense, and Don Luskin, Trend Macro; and America's warriors are being denied the right to vote, with Kyndra Rotunda, Military Voter Protection Project.

  • American Grounds All 757 Aircrafts

    The FDA recalled a contaminated batch of a steroid drug given by spinal injection for back pain, and American Airlines is grounding all 48 of its Boeing 757 aircrafts as they fix the seat lock mechanism that was the cause of seats coming loose, reports CNBC's Seema Mody.

  • Interest Rate

    The average rate on the 30-year fixed mortgage held steady this week, staying slightly above the lowest level on record.

  • Cans of Monster Beverage Corp. energy drinks are arranged for a photograph in San Francisco, California, U.S., on Monday, April 30, 2012. Monster Beverage Corp. surged the most in almost eight years after the Wall Street Journal reported Coca-Cola Co. is in talks to buy the maker of energy drinks.

    The headlines on Monster Beverage are all about health concerns as at least one state’s attorney general investigates its products. But there may be something even bigger: Monster’s growth may be showing signs of peaking.

  • laptop_money_200.jpg

    The first rule of insider trading: Don’t talk about insider trading—or do a lot of Internet searches about it.